ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Want to see AVBP full AI Analyst Report?
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Select Model
Select Model
Rating:58Neutral
Price Target:
$30.00
▲(1.21% Upside)
Action:ReiteratedDate:04/10/26
The score is driven primarily by mixed financial fundamentals—minimal leverage and a stronger capital base, but no revenue and accelerating losses/cash burn. Technicals are supportive with the stock trading above major moving averages and positive MACD. Valuation is constrained by ongoing losses (negative P/E) and lack of dividend data, while the recent positive pipeline event provides incremental support but remains early-stage.
Positive Factors
Low leverage / strong capital base
Near-zero debt and a materially larger equity base give ArriVent funding flexibility and lower financial distress risk over the next 2–6 months. This durable capital structure supports continued R&D spending and reduces immediate refinancing pressure while clinical programs advance.
Negative Factors
No revenue / pre-commercial profile
As a pre-revenue biotech, ArriVent lacks operational cash inflows, making long-term sustainability contingent on clinical outcomes and external financing. This structural reliance increases dilution and funding risk until a commercial product is approved and revenue-generating.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong capital base
Near-zero debt and a materially larger equity base give ArriVent funding flexibility and lower financial distress risk over the next 2–6 months. This durable capital structure supports continued R&D spending and reduces immediate refinancing pressure while clinical programs advance.
Read all positive factors
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.34B
Dividend YieldN/A
Average Volume (3M)499.98K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-86.21%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.47
Shares Outstanding46,368,443
10 Day Avg. Volume471,139
30 Day Avg. Volume499,983
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.69
Forecast
1Y Price Target
$44.56Price Target Upside50.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.77
Revenue Forecast (FY)N/A
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the develo...
How the Company Makes Money
null...
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -177.53M | -80.49M | -74.59M | 0.00 | -51.61M |
| Net Income | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Balance Sheet | |||||
| Total Assets | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Cash, Cash Equivalents and Short-Term Investments | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Total Debt | 14.00K | 176.00K | 317.00K | 139.00K | 0.00 |
| Total Liabilities | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Stockholders Equity | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
Cash Flow | |||||
| Free Cash Flow | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating Cash Flow | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Investing Cash Flow | -71.23M | -192.47M | 0.00 | 0.00 | -40.00M |
| Financing Cash Flow | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Positive
29.64
Price Trends
23.92
Positive
23.10
Positive
21.33
Positive
Market Momentum
1.54
Negative
70.85
Negative
93.51
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Positive. The current price of 29.64 is above the 20-day moving average (MA) of 24.83, above the 50-day MA of 23.92, and above the 200-day MA of 21.33, indicating a bullish trend. The MACD of 1.54 indicates Negative momentum. The RSI at 70.85 is Negative, neither overbought nor oversold. The STOCH value of 93.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 92 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ArriVent BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.92B | -9.66 | -56.07% | ― | 3.42% | -11.04% | |
58 Neutral | $1.34B | -5.44 | -62.48% | ― | ― | -86.21% | |
54 Neutral | $1.59B | -4.65 | -50.17% | ― | 34.26% | 23.00% | |
52 Neutral | $2.40B | -6.10 | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.49B | -4.79 | -145.81% | ― | -10.44% | 19.99% | |
47 Neutral | $1.10B | -3.56 | 1870.38% | ― | -50.80% | 14.80% |
* Healthcare Sector Average
AVBP
ArriVent BioPharma, Inc.
29.50
9.35
46.40%
QURE
uniQure
27.66
14.87
116.26%
IOVA
Iovance Biotherapeutics
3.62
1.87
106.86%
RLAY
Relay Therapeutics
12.76
9.76
325.33%
IVA
Inventiva
5.37
1.75
48.34%
TSHA
Taysha Gene Therapies
6.81
4.68
219.72%
ArriVent BioPharma, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
Positive
Mar 17, 2026
On March 17, 2026, ArriVent BioPharma announced it would present new preclinical data on its EGFR inhibitor firmonertinib and dual-target MUC16/NaPi2b tetravalent ADC ARR-002 at the 2026 American Association for Cancer Research Annual Meeting in S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.